Galliprant (grapiprant tablets) is a prescription nonsteroidal anti-inflammatory drug (NSAID) approved by the FDA for the control of pain and inflammation associated with osteoarthritis in dogs. It belongs to a newer class called piprants, and it works by a different mechanism than traditional NSAIDs like carprofen, meloxicam, or firocoxib. That difference has led many veterinarians and owners to consider Galliprant as a first-line or alternative option — but "different mechanism" does not mean "no monitoring needed," and it does not mean it can be combined with other anti-inflammatory drugs.

This article explains what grapiprant does at the receptor level, what the FDA label says about safety and monitoring, when it fits into a multimodal osteoarthritis plan, and when it does not.

Quick answer

Galliprant is an oral, once-daily NSAID that selectively blocks the EP4 prostaglandin receptor rather than inhibiting the COX-1 and COX-2 enzymes upstream. The label dose is 2 mg/kg once daily. It comes in three flavored tablet sizes (20 mg, 60 mg, and 100 mg). It is approved for dogs 9 months of age and older weighing at least 8 pounds.

Because it does not broadly suppress COX enzymes, it spares many of the protective prostaglandins that maintain kidney blood flow, stomach lining integrity, and blood clotting. In theory, this gives it a different adverse-event profile than traditional NSAIDs. In practice, the label still classifies it as an NSAID, carries the same class warnings about gastrointestinal, renal, and hepatic toxicity, and recommends baseline bloodwork and periodic monitoring.

How grapiprant works — and how it differs from traditional NSAIDs

Traditional NSAIDs work by blocking cyclooxygenase (COX) enzymes. COX-1 and COX-2 convert arachidonic acid into prostaglandins — signaling molecules involved in pain, inflammation, fever, stomach protection, kidney blood flow, and blood clotting. When you inhibit COX enzymes broadly, you reduce pain and inflammation, but you also suppress the protective prostaglandins that keep the stomach lining intact and maintain renal perfusion.

Grapiprant takes a different route. Instead of blocking the enzymes that make prostaglandins, it blocks a single receptor — the EP4 receptor — through which prostaglandin E2 (PGE2) mediates its pain and inflammation effects. The EP4 receptor is the primary mediator of PGE2-elicited sensitization of sensory neurons. By antagonizing EP4 specifically, grapiprant reduces arthritis pain while leaving other prostaglandin pathways (those mediated by EP1, EP2, EP3 receptors) relatively intact.

This is why the label describes Galliprant as a "non-cyclooxygenase inhibiting, non-steroidal anti-inflammatory drug." The FDA has taken the position that this distinction matters in marketing — in 2018, the FDA sent Elanco an untitled letter for promotional materials that described Galliprant as a "prostaglandin receptor antagonist" without also using the term NSAID, which the FDA said was misleading because the drug carries the same class risks.

What the label says about safety

Contraindications

• Do not use in dogs with known hypersensitivity to grapiprant.
• Do not use concomitantly with other NSAIDs or corticosteroids.

Precautions

• Safe use has not been evaluated in dogs younger than 9 months or weighing less than 8 pounds (3.6 kg).
• Safe use has not been evaluated in dogs used for breeding, or in pregnant or nursing dogs.
• Safe use has not been evaluated in dogs with cardiac disease. The label notes that EP4 receptors are "abundantly expressed in the heart of dogs," but states that "the clinical relevance of this is unknown."
• Concurrent use with other anti-inflammatory drugs or protein-bound drugs — including cardiac, anticonvulsant, and behavioral medications — has not been studied.
• Dogs with pre-existing kidney, liver, or cardiovascular disease, or dogs that are dehydrated or on diuretic therapy, are at greatest risk for NSAID adverse events.

Common adverse events

From the controlled field study (285 dogs evaluated):

• Vomiting
• Diarrhea
• Soft or mucoid stools
• Decreased appetite

The label also notes post-approval experience of bloody stools, decreases in serum albumin and total protein, and concurrent elevations in alkaline phosphatase and alanine aminotransferase values.

Class warnings

Although grapiprant does not inhibit COX enzymes, the label includes the full NSAID class warning: "As a class, NSAIDs may be associated with gastrointestinal, renal, and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID."

Dosing and administration

The target dose is 2 mg/kg once daily. For dogs outside these ranges, the label provides instructions on combining tablets.

Galliprant is most effective when given on an empty stomach — food reduces absorption. The label states that pain control may vary from dog to dog, and that the lowest effective dose for the shortest duration consistent with individual response should be used.

If a dose is missed, it should be given as soon as possible unless it is close to the next scheduled dose. Do not double-dose.

Switching between Galliprant and other NSAIDs

Galliprant must not be given at the same time as another NSAID or a corticosteroid (such as prednisone or dexamethasone). When switching from another NSAID to Galliprant — or from Galliprant to another NSAID — a washout period is required. The label does not specify an exact washout duration; veterinarians typically use 3 to 7 days depending on the drugs involved and the dog's health status. This decision should always be made by the prescribing veterinarian.

Monitoring

Even though grapiprant's mechanism spares many protective prostaglandin pathways, the label recommends:

• Baseline bloodwork before starting long-term therapy, including kidney values, liver enzymes, and a complete blood count.
• Periodic monitoring during treatment. The label states: "If Galliprant is used long term, appropriate monitoring is recommended."
• Watching for GI signs (vomiting, diarrhea, bloody or dark stools, decreased appetite), changes in drinking or urination, lethargy, or jaundice.

Monitoring frequency depends on the dog's age, comorbidities, and how long they have been on the drug. Many veterinarians recheck bloodwork every 6 to 12 months for stable dogs on long-term NSAID therapy, including Galliprant.

MDR1 gene mutation

Veterinary Information Network (VIN) notes that dogs with the MDR1 (multi-drug resistance) gene mutation — common in herding breeds such as Collies, Australian Shepherds, and related crosses — have altered metabolism of grapiprant and may be more prone to intestinal side effects. A dose reduction may be needed in affected dogs. If your dog is an affected breed, discuss MDR1 testing with your veterinarian before starting Galliprant.

When Galliprant may fit well

• Dogs with mild to moderate OA pain where a daily oral medication is acceptable.
• Dogs that have experienced GI side effects from a traditional NSAID and need a different option.
• Senior dogs where the different mechanism may offer a more conservative side-effect profile, particularly if kidney values are borderline.
• Dogs already receiving gabapentin or amantadine for multimodal pain control — grapiprant works through a different pathway and can be combined with these non-NSAID adjuncts.

When Galliprant may not be the right choice

Galliprant as part of a multimodal OA plan

Osteoarthritis in dogs is a chronic disease that rarely responds to a single intervention. Current guidelines from the COAST development group and AAHA recommend a multimodal approach:

1. Weight management. Reducing body weight by even 10–15% can significantly improve lameness and mobility in arthritic dogs.
2. Exercise modification. Controlled leash walks, swimming, and underwater treadmill therapy help maintain muscle mass without overstressing joints.
3. Environmental modification. Non-slip flooring, ramps, raised food bowls, and orthopedic bedding reduce daily joint stress.
4. Pain medication. Galliprant, traditional NSAIDs, Librela (bedinvetmab), gabapentin, amantadine, or Adequan Canine (PSGAG) — selected based on the individual dog's needs, comorbidities, and owner preferences.
5. Joint supplements. Omega-3 fatty acids, glucosamine/chondroitin, and green-lipped mussel extract have mixed evidence but may provide adjunctive benefit in some dogs.
6. Physical rehabilitation. Laser therapy, therapeutic ultrasound, range-of-motion exercises, and acupuncture may complement pharmacologic pain control.

Galliprant fits into step 4 as a daily oral NSAID option with a different receptor target. It does not replace steps 1–3 or 5–6.

What to discuss with your veterinarian

• Has my dog had baseline bloodwork recently? Kidney and liver values should be checked before starting any NSAID, including Galliprant.
• What is the plan for monitoring? Ask how often bloodwork should be rechecked and what signs to watch for at home.
• Is my dog on any medication that could interact? Specifically mention any other NSAIDs, steroids, seizure medications, heart medications, or behavioral drugs.
• What if Galliprant does not provide enough relief? Discuss whether a switch to a traditional NSAID, addition of Librela, or referral for physical rehabilitation is the next appropriate step.
• Is my dog an MDR1-affected breed? If so, dose adjustment may be needed.
• What is the expected timeline for improvement? Galliprant is not a rapid-acting drug. Consistent daily dosing for 2–4 weeks is typically needed before assessing whether it is working for an individual dog.

Key points

• Galliprant is an NSAID that selectively blocks the EP4 prostaglandin receptor rather than inhibiting COX enzymes, giving it a different side-effect profile than traditional NSAIDs.
• It is FDA-approved for OA pain in dogs 9 months and older weighing at least 8 pounds.
• Common side effects are GI-related: vomiting, diarrhea, soft stools, and decreased appetite.
• It cannot be combined with other NSAIDs or corticosteroids. A washout period is required when switching.
• The label still carries the full NSAID class warning for gastrointestinal, kidney, and liver risks. Monitoring matters.
• It works best as part of a multimodal OA plan that includes weight management, exercise modification, and environmental changes.

Sources

• FDA — Animal Drug Safety-Related Labeling Changes: Galliprant. https://www.fda.gov/animal-veterinary/drug-labels/animal-drug-safety-related-labeling-changes
• FDA — Warning Letter to Elanco Animal Health Regarding Galliprant (grapiprant). https://www.fda.gov/media/113226/download
• DailyMed — GALLIPRANT (grapiprant tablet) Full Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a38cc5c6-93e8-4c90-aabc-33bc8423beab
• Elanco — Galliprant First Line Choice Technical Bulletin. https://assets.elanco.com/0cec44ed-3eaa-0009-2029-666567e7e4de/45153fb9-9464-41f5-acb4-750819fbd4f6/Galliprant%20First%20Line%20Choice%20Technical%20Bulletin.pdf
• Veterinary Partner (VIN) — Grapiprant (Galliprant). https://veterinarypartner.vin.com/doc/?id=7933279&pid=19239
• Cachon T et al. (2023) — COAST Development Group's International Consensus Guidelines for the Treatment of Canine Osteoarthritis. Frontiers in Animal Science. https://doi.org/10.3389/fvets.2023.1137888
• AAHA — Guidelines for Canine Osteoarthritis Management. https://www.aaha.org/globalassets/02-guidelines/osteoarthritis/osteoarthritis-guidelines.pdf